#GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use
Now, lets look at how these dosing schedules translate into real-world results
Dr Emma Wedgeworth, consultant dermatologist and British Skin Foundation spokesperson, helps explain
Prime/MRx has been at the forefront of GLP-1 insights since we released our year-one research, and though we continue to see declines in persistence and adherence, we are committed to providing clients with actionable data and insights that can steer positive health outcomes for individuals, said David Lassen, PharmD, chief clinical officer at Prime/MRx
Can vary with work or activities that require regular active mouth movements Repeated treatments are necessary to maintain results